Interferon & HIV

Luis J. Montaner DVM, D.Phil, of the Wistar Institute in Philadelphia, Pennsylvania has been studying the effects of interferon on HIV DNA and its...

Calling Out the Media’s Racism & Xenophobia: HIV Is Not a...

Color Blind A new report documents racism and xenophobia in HIV non-disclosure media coverage in Canada by Larry Buhl A new report documents the anti-Black and anti-immigrant...

Cuts to Healthcare

Treatment Horizons by Chael Needle Hill & Mountain? Weakened federal support of HIV/AIDS services puts our health at risk President Obama’s fiscal year 2014 budget plan includes...

Monoclonal Antibodies

Stronger Punch? Monoclonal antibodies provide new hope for easier dosing by Jeannie Wraight With multi-drug, once-a-day therapies now available for use, the push for additional easier to...

Have Some Guts

Is there more benefit to probiotics than we thought? by Jeannie Wraight Probiotics are live microorganisms that help to preserve the good bacteria and balance of...

Early Bird

Study results show immediate treatment holds promise as a prevention tool by Chael Needle Treatment and prevention make good bedfellows. That’s the idea underscoring the results...

Year in Review

What were the top five HCV-related stories of 2012? by Larry Buhl There were many important news stories about hepatitis in 2012. In this column we...

Cutting Glass

A study links anal sex & meth to increased HCV rates among MSMs by Larry Buhl LifeGuide For decades it has been the conventional wisdom that...

Women’s HIV Program: Empowerment Is Treatment

Undetectable is a worthy goal, no doubt about it. A suppressed viral load very often means the individual living with HIV is adherent to...

Introducing Dolutegravir

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...